Amicogen, Inc. (092040.KQ)
KRW 3930.0
(-3.2%)
KRW 3930.0
(-3.2%)
| Year | Eps | Eps Growth |
|---|---|---|
| 2023 | -583.58 KRW | 47.07% |
| 2022 | -1102.58 KRW | -1341.92% |
| 2021 | 88.78 KRW | -88.3% |
| 2020 | 758.88 KRW | 36384.62% |
| 2019 | 2.08 KRW | -99.78% |
| 2018 | 965.42 KRW | 946.56% |
| 2017 | -114.04 KRW | -387.98% |
| 2016 | 39.60 KRW | -26.04% |
| 2015 | 53.54 KRW | -75.75% |
| 2014 | 220.75 KRW | -11.43% |
| 2013 | 249.25 KRW | 0.0% |
| Year | Eps | Eps Growth |
|---|---|---|
| 2024 Q2 | -170.08 KRW | -67.72% |
| 2024 Q1 | -101.36 KRW | 74.62% |
| 2023 FY | - KRW | 47.07% |
| 2023 Q3 | -6.45 KRW | 91.25% |
| 2023 Q1 | 44.21 KRW | 106.72% |
| 2023 Q4 | -399.30 KRW | -6090.7% |
| 2023 Q2 | -73.73 KRW | -266.77% |
| 2022 Q4 | -658.06 KRW | -5676.78% |
| 2022 FY | - KRW | -1341.92% |
| 2022 Q3 | 11.80 KRW | 104.5% |
| 2022 Q2 | -262.21 KRW | -28.92% |
| 2022 Q1 | -203.39 KRW | 57.93% |
| 2021 FY | - KRW | -88.3% |
| 2021 Q4 | -483.40 KRW | 2.15% |
| 2021 Q2 | 1123.78 KRW | 2637.32% |
| 2021 Q1 | -44.29 KRW | -119.01% |
| 2021 Q3 | -494.04 KRW | -143.96% |
| 2020 FY | - KRW | 36384.62% |
| 2020 Q1 | -245.58 KRW | -187.58% |
| 2020 Q2 | 636.39 KRW | 359.14% |
| 2020 Q3 | 198.00 KRW | -68.89% |
| 2020 Q4 | 232.94 KRW | 17.65% |
| 2019 Q3 | -300.00 KRW | 51.82% |
| 2019 Q1 | 643.51 KRW | 21.22% |
| 2019 FY | - KRW | -99.78% |
| 2019 Q4 | 280.40 KRW | 193.47% |
| 2019 Q2 | -622.65 KRW | -196.76% |
| 2018 Q2 | 467.22 KRW | 1655.15% |
| 2018 FY | - KRW | 946.56% |
| 2018 Q4 | 530.87 KRW | 10517.4% |
| 2018 Q3 | 5.00 KRW | -98.93% |
| 2018 Q1 | 26.62 KRW | 111.65% |
| 2017 FY | - KRW | -387.98% |
| 2017 Q1 | -5.08 KRW | -115.58% |
| 2017 Q2 | 14.44 KRW | 384.25% |
| 2017 Q3 | -28.00 KRW | -293.91% |
| 2017 Q4 | -228.50 KRW | -716.07% |
| 2016 FY | - KRW | -26.04% |
| 2016 Q4 | 32.60 KRW | 195.18% |
| 2016 Q3 | -34.25 KRW | -198.34% |
| 2016 Q2 | -11.48 KRW | -120.47% |
| 2016 Q1 | 56.08 KRW | 64.89% |
| 2015 Q3 | -22.25 KRW | -202.11% |
| 2015 Q2 | 21.79 KRW | -12.03% |
| 2015 Q1 | 24.77 KRW | -78.22% |
| 2015 FY | - KRW | -75.75% |
| 2015 Q4 | 34.01 KRW | 252.85% |
| 2014 Q2 | 15.91 KRW | -82.41% |
| 2014 Q1 | 90.43 KRW | 154.09% |
| 2014 Q3 | 34.50 KRW | 116.84% |
| 2014 Q4 | 113.71 KRW | 229.59% |
| 2014 FY | - KRW | -11.43% |
| 2013 Q4 | 35.59 KRW | 103.37% |
| 2013 FY | - KRW | 0.0% |
| 2013 Q2 | 87.63 KRW | 11.28% |
| 2013 Q3 | 17.50 KRW | -80.03% |
| 2013 Q1 | 78.75 KRW | 0.0% |
| 2012 Q3 | 42.00 KRW | 0.0% |
| Name | Eps | Eps Difference |
|---|---|---|
| HLB Co., Ltd. | -1559.61 KRW | 62.582% |
| iNtRON Biotechnology, Inc. | -292.11 KRW | -99.781% |
| BINEX Co., Ltd. | 151.04 KRW | 486.374% |
| Bioneer Corporation | -410.19 KRW | -42.271% |
| Anterogen.Co.,Ltd. | -291.93 KRW | -99.904% |
| MEDIPOST Co., Ltd. | 287.00 KRW | 303.338% |
| CrystalGenomics, Inc. | -661.00 KRW | 11.713% |
| Helixmith Co., Ltd | -1543.76 KRW | 62.197% |
| Chabiotech Co.,Ltd. | -149.80 KRW | -289.573% |
| Medy-Tox Inc. | 1456.65 KRW | 140.063% |
| Peptron, Inc. | -773.61 KRW | 24.564% |
| Genexine, Inc. | -1652.14 KRW | 64.677% |
| HLB Therapeutics Co.,Ltd. | -32.12 KRW | -1716.874% |
| LegoChem Biosciences, Inc. | -2595.00 KRW | 77.511% |
| ALTEOGEN Inc. | -65.27 KRW | -794.101% |
| PharmaResearch Co., Ltd. | 7502.00 KRW | 107.779% |
| SillaJen, Inc. | -179.98 KRW | -224.247% |
| JETEMA, Co., Ltd. | 783.21 KRW | 174.511% |
| OliX Pharmaceuticals,Inc | -1323.81 KRW | 55.917% |
| Genomictree Inc. | -391.00 KRW | -49.253% |
| MedPacto, Inc. | -1664.87 KRW | 64.947% |
| D&D Pharmatech | 409.19 KRW | 242.618% |
| EASY BIO,Inc. | 455.00 KRW | 228.259% |
| GI Innovation, Inc. | -1285.69 KRW | 54.61% |